Introduction Korea Prime Pharm Co., LTD. is engaged primarily in developing and producing better drugs. The Company comprises highly talented professionals with long-accumulated extended knowledge and experiences in the field of medical research. In particular, CEO of the Company, Dae-Ik Kim, has made our best efforts to move ahead in pharmaceutical industry and eventually grown up to the highest growth potential company in Korea. The company acquired exclusive licensing rights of three proprietary technologies for improving biologic protein drugs and has maintained ~52 international patents- Emerging company in Korea The Company has developed targets for the biogenerics close to patent expiry. The Company has the proprietary and innovative technologies which can enable drug lifecycle extension and improve efficacy and potency of protein drugs. So we are in the process of commercializing its patented candidates and technologies. Our patents consist of accumulated data showing efficacy and safety improvements using its platform technologies. Recently the Company is preparing for clinical trials and promoting partnership with global pharmaceutical companies. By partnering strategies including licensing, end marketing, manufacturing, commercialization arrangements, its value and profits can be maximized. erythropoietin, orencia, enbrel, Thrombopoietin, Granulocyte colony-stimulating factor, pharmaceutical, Pharm : (1) erythropoietin : It is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine (protein signaling molecule) for erythrocyte (red blood cell) precursors in the bone marrow. Erythropoietin is the hormone that regulates red blood cell production. It also has other known biological functions. For example, erythropoietin plays an important role in the brain's response to neuronal injury. (2) orencia : Abatacept (marketed as Orencia) is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4. It is a molecule capable of binding with more avidity to CD80 (B7-1) than to CD86 (B7-2). Abatacept is a selective co-stimulation modulator as it inhibits the costimulation of T cells. It was is licensed for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNF? therapy. (3) enbrel : Etanercept (trade name Enbrel) is a drug that treats autoimmune diseases by interfering with tumor necrosis factor (TNF; a soluble inflammatory cytokine) by acting as a TNF inhibitor. Etanercept is a fusion protein produced through expression of recombinant DNA. That is, it is a product of a DNA "construct" engineered to link the human gene for soluble TNF receptor 2 to the gene for the Fc component of human immunoglobulin G1 (IgG1). (4) Thrombopoietin : Thrombopoietin (TPO) also known as megakaryocyte growth and development factor (MGDF) is a protein that in humans is encoded by the TPO gene. Thrombopoietin is a glycoprotein hormone produced mainly by the liver and the kidney that regulates the production of platelets by the bone marrow. It stimulates the production and differentiation of megakaryocytes, the bone marrow cells that fragment into large numbers of platelets. (5) Granulocyte colony-stimulating factor : Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. G-CSF is also known as colony-stimulating factor 3 (CSF 3). It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood. G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.